Compare CRNX & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | BGSI |
|---|---|---|
| Founded | 2008 | 1990 |
| Country | United States | Canada |
| Employees | N/A | 13449 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | 2018 | N/A |
| Metric | CRNX | BGSI |
|---|---|---|
| Price | $36.70 | $97.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | $76.75 | ★ $157.00 |
| AVG Volume (30 Days) | ★ 1.0M | 24.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,039,000.00 | N/A |
| Revenue This Year | $720.10 | $35.07 |
| Revenue Next Year | $184.67 | $8.01 |
| P/E Ratio | ★ N/A | $231.07 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $88.97 |
| 52 Week High | $57.99 | $183.10 |
| Indicator | CRNX | BGSI |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 44.72 |
| Support Level | $33.14 | $94.77 |
| Resistance Level | $44.89 | $110.36 |
| Average True Range (ATR) | 1.63 | 3.44 |
| MACD | 0.29 | 0.61 |
| Stochastic Oscillator | 68.55 | 56.25 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.